Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.

By Srijan Sen, R. Duman, G. Sanacora. Biological Psychiatry, 2008

1,210 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/04ab9f7efd174b74bdb288ec8504fd0fc8523af6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. T. Rantamäki
2. L. Monteggia
3. Anita E. Autry
4. Eero Castrén
5. M. Otto
6. Kristin L. Szuhany
7. David E. Nichols
8. Matteo Bugatti

In Pharmacology

1. Eero Castrén
2. David E. Nichols
3. Anita E. Autry
4. L. Monteggia

Citations in the corpus

• A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor (2014, result): “…the possibility that programs of exercise may help rescue the low resting BDNF levels often observed in depressed patients (Brunoni et al., 2008; Piccinni et al., 2008) and exercise produces effects in a similar range to those of antidepressants (d = 0.62 for antidepressants, Sen et al., 2008).”
• Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “…of cortical BDNF (associated with neuronal growth, differentiation and synaptogenesis) (Hsu et al., 2015); decreased cortical BDNF is associated with major depression in humans (Duman, 2004); and cortical BDNF normalizes with anti-depressant treatment (Sen et al., 2008; Shimizu et al., 2003).”
• Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders (2012, positive): “In addition, studies in live patients indicate that serum levels of BDNF are normalized in patients suffering from depression after long-term antidepressant treatment (Duman and Monteggia, 2006), a finding that has been validated after meta-analyses of multiple studies (Sen et al., 2008).”
• Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011, background): “, and several antidepressant therapies — including serotonin reuptake inhibitors, tricyclic antidepressants and electroconvulsive shock — have been reported to normalize serum BDNF level”
• Psychedelics (2016, background): “…through stimulation of a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid–type glutamate receptors and subsequent increase in the level of BDNF. SerumBDNF levels are abnormally low in depressed individuals and treatment with antidepressants is known to normalize BDNF levels (Sen et al., 2008).”
• The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity (2010, background): “Several studies have shown that serum BDNF levels are reduced in depressed patients and can be normalized by successful treatment (Karege et al., 2005; Monteleone et al., 2008; Sen et al., 2008).”